These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 32378251)

  • 1. Baseline characteristics of patients with atypical haemolytic uraemic syndrome (aHUS): The Australian cohort in a global aHUS registry.
    Soraru J; Isbel N; Wong G; Coates PT; Mantha M; Abraham A; Juneja R; Hsu D; Brown F; Bose B; Mudge D; Carroll R; Kausman J; Hughes P; Barbour T; Durkan A; Mount P; Lee D; Larkins N; Ranganathan D; Lim WH
    Nephrology (Carlton); 2020 Sep; 25(9):683-690. PubMed ID: 32378251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.
    Mallett A; Hughes P; Szer J; Tuckfield A; Van Eps C; Cambell SB; Hawley C; Burke J; Kausman J; Hewitt I; Parnham A; Ford S; Isbel N
    Intern Med J; 2015 Oct; 45(10):1054-65. PubMed ID: 26247170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A patient with a homozygous diacylglycerol kinase epsilon (DGKE) gene mutation with atypical haemolytic uraemic syndrome and low C3 responded well to eculizumab: a case report.
    Alabdulqader M; Alfakeeh K
    BMC Nephrol; 2021 Apr; 22(1):140. PubMed ID: 33879077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver transplantation for aHUS: still needed in the eculizumab era?
    Coppo R; Bonaudo R; Peruzzi RL; Amore A; Brunati A; Romagnoli R; Salizzoni M; Galbusera M; Gotti E; Daina E; Noris M; Remuzzi G
    Pediatr Nephrol; 2016 May; 31(5):759-68. PubMed ID: 26604087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.
    Duineveld C; Verhave JC; Berger SP; van de Kar NCAJ; Wetzels JFM
    Am J Kidney Dis; 2017 Dec; 70(6):770-777. PubMed ID: 28821363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS).
    Wong E; Challis R; Sheerin N; Johnson S; Kavanagh D; Goodship TH
    Immunobiology; 2016 Jun; 221(6):715-8. PubMed ID: 26037115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.
    Campistol JM; Arias M; Ariceta G; Blasco M; Espinosa L; Espinosa M; Grinyó JM; Macía M; Mendizábal S; Praga M; Román E; Torra R; Valdés F; Vilalta R; Rodríguez de Córdoba S
    Nefrologia; 2015; 35(5):421-47. PubMed ID: 26456110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis.
    Fakhouri F; Scully M; Ardissino G; Al-Dakkak I; Miller B; Rondeau E
    J Nephrol; 2021 Oct; 34(5):1581-1590. PubMed ID: 33826112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome.
    Zuber J; Frimat M; Caillard S; Kamar N; Gatault P; Petitprez F; Couzi L; Jourde-Chiche N; Chatelet V; Gaisne R; Bertrand D; Bamoulid J; Louis M; Sberro Soussan R; Navarro D; Westeel PF; Frimat L; Colosio C; Thierry A; Rivalan J; Albano L; Arzouk N; Cornec-Le Gall E; Claisse G; Elias M; El Karoui K; Chauvet S; Coindre JP; Rerolle JP; Tricot L; Sayegh J; Garrouste C; Charasse C; Delmas Y; Massy Z; Hourmant M; Servais A; Loirat C; Fakhouri F; Pouteil-Noble C; Peraldi MN; Legendre C; Rondeau E; Le Quintrec M; Frémeaux-Bacchi V
    J Am Soc Nephrol; 2019 Dec; 30(12):2449-2463. PubMed ID: 31575699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interventions for atypical haemolytic uraemic syndrome.
    Pugh D; O'Sullivan ED; Duthie FA; Masson P; Kavanagh D
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD012862. PubMed ID: 33783815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation.
    Okumi M; Tanabe K
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():9-13. PubMed ID: 26988663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Kato H; Miyakawa Y; Hidaka Y; Inoue N; Ito S; Kagami S; Kaname S; Matsumoto M; Mizuno M; Matsuda T; Shimono A; Maruyama S; Fujimura Y; Nangaku M; Okada H
    Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical Hemolytic Uremic Syndrome: New Challenges in the Complement Blockage Era.
    Avila Bernabeu AI; Cavero Escribano T; Cao Vilarino M
    Nephron; 2020; 144(11):537-549. PubMed ID: 32950988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome- a single center experience.
    Kant S; Bhalla A; Alasfar S; Alachkar N
    BMC Nephrol; 2020 May; 21(1):189. PubMed ID: 32434487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eculizumab in secondary atypical haemolytic uraemic syndrome.
    Cavero T; Rabasco C; López A; Román E; Ávila A; Sevillano Á; Huerta A; Rojas-Rivera J; Fuentes C; Blasco M; Jarque A; García A; Mendizabal S; Gavela E; Macía M; Quintana LF; María Romera A; Borrego J; Arjona E; Espinosa M; Portolés J; Gracia-Iguacel C; González-Parra E; Aljama P; Morales E; Cao M; Rodríguez de Córdoba S; Praga M
    Nephrol Dial Transplant; 2017 Mar; 32(3):466-474. PubMed ID: 28339660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome.
    Huerta A; Arjona E; Portoles J; Lopez-Sanchez P; Rabasco C; Espinosa M; Cavero T; Blasco M; Cao M; Manrique J; Cabello-Chavez V; Suñer M; Heras M; Fulladosa X; Belmar L; Sempere A; Peralta C; Castillo L; Arnau A; Praga M; Rodriguez de Cordoba S
    Kidney Int; 2018 Feb; 93(2):450-459. PubMed ID: 28911789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical issues in using eculizumab for children with atypical haemolytic uraemic syndrome in the acute phase: A review of four patients.
    Terano C; Ishikura K; Hamada R; Yoshida Y; Kubota W; Okuda Y; Shinozuka S; Harada R; Iyoda S; Fujimura Y; Hamasaki Y; Hataya H; Honda M
    Nephrology (Carlton); 2018 Jun; 23(6):539-545. PubMed ID: 28387984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved Renal Recovery with Eculizumab Therapy among Children with High Prevalence of Mutation-Associated Atypical Hemolytic Uremic Syndrome: A Retrospective Cohort Study.
    Bamhraz AA; Rahim KA; Faqeehi HY; Alanazi A
    Kidney Blood Press Res; 2020; 45(6):939-954. PubMed ID: 33238263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.
    Krishnappa V; Gupta M; Elrifai M; Moftakhar B; Ensley MJ; Vachharajani TJ; Sethi SK; Raina R
    Ther Apher Dial; 2018 Apr; 22(2):178-188. PubMed ID: 29250893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful 7-Year Eculizumab Treatment of Plasmapheresis-Resistant Recurrent Atypical Hemolytic-Uremic Syndrome due to Complement Factor H Hybrid Gene: A Case Report.
    Vondrák K; Seeman T
    Transplant Proc; 2018 Apr; 50(3):967-970. PubMed ID: 29661469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.